Publication:
Optimizing radiotherapy with immunotherapeutic approaches

dc.contributor.coauthorSchoenhals, Jonathan E.
dc.contributor.coauthorSkrepnik, Tijana
dc.contributor.coauthorCortez, Maria A.
dc.contributor.coauthorLi, Ailin
dc.contributor.coauthorWelsh, James W.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorSelek, Uğur
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:23:18Z
dc.date.issued2017
dc.description.abstractSeveral factors must be considered to successfully integrate immunotherapy with radiation into clinical practice. One such factor is that concepts arising from preclinical work must be tested in combination with radiation in preclinical models to better understand how combination therapy will work in patients; examples include checkpoint inhibitors, tumor growth factor-beta (TGF-beta) inhibitors, and natural killer (NK) cell therapy. Also, many radiation fields and fractionation schedules typically used in radiation therapy had been standardized before the introduction of advanced techniques for radiation planning and delivery that account for changes in tumor size, location, and motion during treatment, as well as uncertainties introduced by variations in patient setup between treatment fractions. As a result, radiation therapy may involve the use of large treatment volumes, often encompassing nodal regions that may not be irradiated with more conformal techniques. Traditional forms of radiation in particular pose challenges for combination trials with immunotherapy. This chapter explores these issues in more detail and provides insights as to how radiation therapy can be optimized to combine with immunotherapy.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume995
dc.identifier.doi10.1007/978-3-319-53156-4_3
dc.identifier.eissn2214-8019
dc.identifier.isbn978-3-319-53156-4
dc.identifier.isbn978-3-319-53155-7
dc.identifier.issn0065-2598
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85015877142
dc.identifier.urihttps://doi.org/10.1007/978-3-319-53156-4_3
dc.identifier.urihttps://hdl.handle.net/20.500.14288/11219
dc.identifier.wos412187400003
dc.keywordsRadiation
dc.keywordsImmunotherapy
dc.keywordsSabr
dc.keywordsSbrt
dc.keywordsCtla4
dc.keywordsPd1
dc.keywordsTgf-Beta
dc.keywordsCd8+T-Cell
dc.keywordsClinical trial melanoma brain metastases
dc.keywordsCell lung-cancer
dc.keywordsResistant prostate-cancer
dc.keywordsLow-dose irradiation
dc.keywordsGrowth-factor-beta
dc.keywordsCd8(+) T-Cells
dc.keywordsRadiation-therapy
dc.keywordsIonizing-radiation
dc.keywordsAntitumor immunity
dc.keywordsStereotactic radiosurgery
dc.language.isoeng
dc.publisherSpringer International Publishing Ag
dc.relation.ispartofImmunotherapy
dc.subjectOncology
dc.subjectImmunology
dc.titleOptimizing radiotherapy with immunotherapeutic approaches
dc.typeBook Chapter
dspace.entity.typePublication
local.contributor.kuauthorSelek, Uğur
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files